Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00184080 | Elsamitrucin (SPP 28090) in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma | PHASE2 | COMPLETED | 7 | — | — | May 1, 2004 | Apr 1, 2006 | May 21, 2014 | 1 | United States |
| Name | Type | Description |
|---|---|---|
| Elsamitrusin | DRUG | - |
Inclusion Criteria: * Histologically confirmed NHL both B and T-cell that is refractory to or has relapsed after standard therapy or for which there is no known effective treatment. * CT or MRI scans confirming measurable tumor size (lymph node must be \>1.0 cm in its longest transverse diameter). ...